Silexion Therapeutics (SLXN)
NASDAQ:SLXN
Top Page
Silexion Therapeutics
(NASDAQ:SLXN)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.00
▼(-52.83% Downside)
Action:ReiteratedDate:03/25/26
The score is held down primarily by weak financial durability (no revenue and ongoing cash burn) and a bearish technical setup (below key moving averages with negative MACD). Corporate events provide some offset via the clinical trial approval, while valuation offers limited support given a non-meaningful negative P/E and no dividend.
Positive Factors
Regulatory milestone
Regulatory clearance to start a Phase 2/3 trial converts Silexion from preclinical to clinical-stage for SIL204, materially de-risks the program, enables human proof-of-concept data generation and makes the asset credible for long-term partnerships and regulatory pathways across jurisdictions.
Negative Factors
No revenue
Silexion remains a development-stage biotech with zero product revenue, implying long-term dependency on successful trials and external funding. Without commercial sales, the firm lacks recurring cash inflows and must convert clinical success into sustainable revenue to achieve durable financial self-sufficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory milestone
Regulatory clearance to start a Phase 2/3 trial converts Silexion from preclinical to clinical-stage for SIL204, materially de-risks the program, enables human proof-of-concept data generation and makes the asset credible for long-term partnerships and regulatory pathways across jurisdictions.
Read all positive factors
Silexion Therapeutics (SLXN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.06M
Dividend YieldN/A
Average Volume (3M)50.14K
Price to Earnings (P/E)―
Beta (1Y)0.34
Revenue GrowthN/A
EPS Growth91.47%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.38
Shares Outstanding3,330,785
10 Day Avg. Volume60,134
30 Day Avg. Volume50,136
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit483.86
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$6.00Price Target Upside183.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.25
Revenue Forecast (FY)N/A
Silexion Therapeutics Business Overview & Revenue Model
Company Description
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its propri...
How the Company Makes Money
null...
Silexion Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
34
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -14.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.62M | -16.48M | -4.64M | -3.80M | -755.00K |
| Net Income | -11.91M | -16.44M | -4.94M | -3.21M | -755.22K |
Balance Sheet | |||||
| Total Assets | 7.21M | 2.86M | 5.26M | 9.33M | 115.41M |
| Cash, Cash Equivalents and Short-Term Investments | 5.99M | 1.19M | 4.59M | 8.26M | 38.94K |
| Total Debt | 468.00K | 4.49M | 171.00K | 271.00K | 0.00 |
| Total Liabilities | 4.61M | 6.85M | 17.31M | 16.41M | 508.92K |
| Stockholders Equity | 2.60M | -3.99M | -15.48M | -10.66M | 114.91M |
Cash Flow | |||||
| Free Cash Flow | -10.83M | -8.42M | -4.54M | -3.38M | -1.41M |
| Operating Cash Flow | -10.82M | -8.40M | -4.53M | -3.33M | -1.41M |
| Investing Cash Flow | -14.00K | -22.00K | 573.00K | -524.00K | 0.00 |
| Financing Cash Flow | 15.64M | 5.10M | 522.00K | 2.75M | 116.40M |
Silexion Therapeutics Technical Analysis
Negative
2.12
Price Trends
1.71
Negative
2.13
Negative
4.95
Negative
Market Momentum
-0.13
Positive
34.31
Neutral
40.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLXN, the sentiment is Negative. The current price of 2.12 is above the 20-day moving average (MA) of 1.57, above the 50-day MA of 1.71, and below the 200-day MA of 4.95, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 34.31 is Neutral, neither overbought nor oversold. The STOCH value of 40.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLXN.
Silexion Therapeutics Risk Analysis
Silexion Therapeutics disclosed 51 risk factors in its most recent earnings report. Silexion Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Silexion Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $29.35M | -0.52 | 0.02% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $5.48M | -25.06 | -418.83% | ― | ― | 98.58% | |
49 Neutral | $7.98M | -0.46 | -684.86% | ― | ― | 96.75% | |
41 Neutral | $4.06M | -0.21 | -529.06% | ― | ― | 91.47% | |
41 Neutral | $870.05K | -0.48 | -1032.82% | ― | -59.21% | 68.97% |
* Healthcare Sector Average
SLXN
Silexion Therapeutics
1.22
-15.28
-92.61%
MBIO
Mustang Bio
0.72
-0.53
-42.16%
LYRA
Lyra Therapeutics
0.49
-5.83
-92.25%
RNAZ
TransCode Therapeutics
8.70
-5.16
-37.23%
AEON
AEON Biopharma
1.16
0.58
100.00%
Silexion Therapeutics Corporate Events
Executive/Board Changes
Silexion Therapeutics Announces Immediate Board Membership Change
Neutral
Mar 25, 2026
On March 25, 2026, Silexion Therapeutics Corp. announced that its Board of Directors unanimously removed Ilan Levin from his position as a board member, effective immediately. The action was taken in writing by all other directors under the compan...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Silexion gains approval for SIL204 pancreatic cancer trial
Positive
Mar 24, 2026
On March 24, 2026, Silexion Therapeutics announced that the Israeli Ministry of Health had approved initiation of a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, following strong anti-tumor activity in multiple preclini...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Silexion Shareholders Reject Capital Increase and Plan Amendments
Negative
Mar 23, 2026
On March 23, 2026, Silexion Therapeutics reconvened an extraordinary general meeting originally held on March 16, 2026, after the first session was adjourned for lack of quorum. Under its articles of association, the shareholders present after a 3...
Business Operations and StrategyProduct-Related Announcements
Silexion Highlights SIL204 RNAi Pancreatic Cancer Program Progress
Positive
Feb 3, 2026
On February 3, 2026, Silexion Therapeutics used a new corporate presentation in a non-deal investor roadshow to highlight the progress and positioning of its RNAi oncology pipeline, led by SIL204, a first-in-class, isoform-selective pan-KRAS silen...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Silexion outlines 2026 plans after transformational 2025 progress
Positive
Jan 6, 2026
On January 6, 2026, Silexion Therapeutics released a CEO letter to shareholders detailing what it called a transformational 2025, highlighted by strong preclinical data for its lead RNAi asset SIL204, which showed over 90% inhibition of KRAS-mutat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.